For US Healthcare Professionals
XARELTO®: Stroke risk reduction in patients with nonvalvular atrial fibrillation (NVAF)
Proven once-daily,* 24-hour stroke risk reduction1,2
*Taken with evening meal.
Demonstrated clinical outcomes in an obesity subgroup and consistent real-world evidence in patients who have NVAF and morbid obesity3,4
NVAF = nonvalvular atrial fibrillation.